Vidac Pharma Holding Plc (HAM:T9G)

Market Cap	26.85M
Revenue	n/a
Net Income	n/a
Shares Out	51.63M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,300
Average Volume	4,653
Open	0.5200
Previous Close	0.5120
Day's Range	0.5200 - 0.5200
52-Week Range	0.4500 - 0.7900
Beta	-0.35
RSI	50.87
Earnings Date	n/a

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors. The company...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2021
• Country: United Kingdom
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: T9G